BiomX Inc. has begun patient dosing in their Phase 2b trial for phage therapy targeting antibiotic-resistant lung infections in Cystic Fibrosis patients, with topline results expected in Q1 2026. Previous efficacy findings showed complete bacterial clearance in 14.3% of patients after 10 days of treatment. FDA feedback is anticipated in H2 2025, potentially streamlining approval for this treatment option. The trial will evaluate BX004 in CF patients with Pseudomonas aeruginosa infections, a leading cause of death in this population.

The Phase 2b trial is a randomized study evaluating BX004 in 60 CF patients with P. aeruginosa infections, with patients randomized to receive BX004 or a placebo for 8 weeks. BiomX is developing BX004 for CF patients with these infections, with promising results from previous studies showing improvements in lung function and reduction in bacterial burden. BiomX is leading the development of phage therapies for chronic diseases with unmet needs.

Read more at GlobeNewswire: BiomX Announces Successful Initiation of Phase 2b Trial